Seeking Alpha

Progenics to relaunch Azedra study

  • Progenics Pharmaceuticals (PGNX) rallies 7% before the bell.
  • The company is restarting a Phase 2b study of Azedra in pheochromocytomas.
  • Molecular Insight Pharmaceuticals suspended the trial back in 2010 in order to find more funding. PGNX acquired the company earlier this year.
  • Once the study is complete, PGNX says it "intends to submit a NDA and request priority review to receive FDA action on the application within six months instead of the standard ten."
  • Azedra has Orphan Drug and Fast Track designations. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: